Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Total Revenue of $228.37 million for fiscal year 2025.
PUMA BIOTECHNOLOGY, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $228.37M -0.9% |
$230.47M -2.2% |
$235.64M +3.3% |
$228.03M -9.9% |
$253.16M +12.5% |
$225.11M -17.3% |
| Revenue (ASC 606) | $228.37M -0.9% |
$230.47M -2.2% |
$235.64M +3.3% |
$228.03M -9.9% |
$253.16M +12.5% |
$225.11M -17.3% |
| Net Income | $31.11M +2.8% |
$30.28M +40.2% |
$21.59M +1079450.0% |
$2.0K +100.0% |
-$29.13M +51.5% |
-$59.99M +20.6% |
| Diluted EPS | $0.61 -1.6% |
$0.62 +37.8% |
$0.45 | $0.00 +100.0% |
-$0.72 +52.6% |
-$1.52 |
| Total Assets | $216.30M +1.4% |
$213.33M -7.5% |
$230.53M +3.8% |
$222.06M -2.0% |
$226.59M -7.2% |
$244.22M +4.0% |
| Cash and Equivalents | $29.64M -57.2% |
$69.22M -18.2% |
$84.58M +11.0% |
$76.20M +20.7% |
$63.13M -26.0% |
$85.29M +42.1% |
| Long-Term Debt | $0.00 -100.0% |
$21.72M -66.9% |
$65.66M -33.2% |
$98.31M +1.3% |
$97.09M +15.6% |
$84.03M -11.5% |
| Stockholders Equity | $130.34M +41.5% |
$92.12M +72.4% |
$53.44M +147.3% |
$21.61M +983.4% |
-$2.45M +58.9% |
-$5.95M -134.1% |
| R&D Expense | — | — | — | — | $71.87M -26.4% |
$97.65M -26.5% |
| Operating Income | $37.30M +20.5% |
$30.97M -5.1% |
$32.64M +37.6% |
$23.72M +1738.8% |
$1.29M +104.2% |
-$30.40M +22.1% |
| Shares Outstanding | 50.41M +2.7% |
49.11M +3.1% |
47.65M +2.8% |
46.35M +12.6% |
41.18M +2.7% |
40.09M +2.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $54.48M | -32.4% | +3.9% |
| Revenue (ASC 606) | September 30, 2025 | $54.48M | -32.4% | +3.9% |
| Net Income | September 30, 2025 | $8.84M | -56.5% | +51.1% |
| Diluted EPS | September 30, 2025 | $0.17 | -58.5% | +41.7% |
| Total Assets | September 30, 2025 | $202.86M | -8.1% | +4.1% |
| Cash and Equivalents | September 30, 2025 | $53.52M | -20.4% | -2.1% |
| Long-Term Debt | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2025 | $115.27M | +62.1% | +10.1% |
| R&D Expense | June 30, 2022 | $11.97M | -35.8% | -21.5% |
| Operating Income | September 30, 2025 | $9.57M | -56.6% | +44.3% |
| Shares Outstanding | September 30, 2025 | 50.38M | +2.7% | +1.0% |
- PUMA BIOTECHNOLOGY, INC. reported Total Revenue of $228.37 million for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -0.9% in Total Revenue compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported Revenue (ASC 606) of $228.37 million for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -0.9% in Revenue (ASC 606) compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported Net Income of $31.11 million for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed an increase of +2.8% in Net Income compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported Diluted EPS of $0.61 per share for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -1.6% in Diluted EPS compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported Total Assets of $216.30 million for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed an increase of +1.4% in Total Assets compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported Cash and Equivalents of $29.64 million for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -57.2% in Cash and Equivalents compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported Long-Term Debt of $0.00 for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported Stockholders Equity of $130.34 million for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed an increase of +41.5% in Stockholders Equity compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported R&D Expense of $71.87 million for fiscal year 2021.
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -26.4% in R&D Expense compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported Operating Income of $37.30 million for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed an increase of +20.5% in Operating Income compared to the prior fiscal year.
- PUMA BIOTECHNOLOGY, INC. reported Shares Outstanding of 50.41 million shares for fiscal year 2025.
- PUMA BIOTECHNOLOGY, INC. showed an increase of +2.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: